A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy; Overweight; Obesity

Treatments: Drug: PF-04620110; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00959426

B0961002

Details and patient eligibility

About

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses of PF-04620110.

Enrollment: 71 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male and/or female subjects between the ages of 18 and 55 years
• Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

71 participants in 2 patient groups, including a placebo group

PF-04620110

Experimental group

Treatment:

Drug: PF-04620110

Placebo Comparator

Placebo Comparator group

Treatment:

Drug: Placebo